-
毒性弥漫性甲状腺肿,即Graves病,约占全部甲状腺功能亢进症(以下简称甲亢)的80%以上。促甲状腺素受体抗体(thyroid stimulating hormone receptor antibody,TRAb)在Graves甲亢发病过程中发挥着重要作用,也是临床确诊Graves甲亢的一个很好的辅助诊断指标[1-4]。131I用于治疗Graves病已被广泛应用。大量文献研究显示,131I治疗后早期,即6个月内,许多患者的血清TRAb异常增高[5],而该TRAb是否具有131I治疗前TRAb[即甲状腺刺激抗体(thyroid stimulating antibody,TSAb)]的同等作用尚不清楚,其功能状态也决定了131I治疗后的甲亢预后,因此,有必要对其进行进一步的观察和研究。
-
观察组TRAb阳性率显著高于对照组(78.6% vs. 36.2%,X2=16.198,P < 0.001);两组间TSAb阳性率比较,差异无统计学意义(38.1% vs. 53.2%,X2=2.034,P > 0.05);但两组内TRAb阳性病例中的TSAb阳性率分别为39.4%和88.2%,对照组的阳性率显著高于观察组(X2=10.862,P < 0.05)(表 1)。
组别 例数 TRAb(U/L) TSAb(U/L) TSBAb(AU/ml) TSAb+TRAb 阳性 阴性 阳性 阴性 阳性 阴性 阳性 阳性率 对照组 47 17 30 25 22 3 44 15 88.2% 观察组 42 33 9 16 26 0 42 13 39.4% 合计 89 50 39 41 48 3 86 28 注:表中,TRAb:促甲状腺素受体抗体;TSAb:甲状腺刺激抗体;TSBAb:甲状腺刺激阻断性抗体;(TSAb+TRAb)阳性表示该病例中的TRAb和TSAb同时异常增高。 表 1 观察组和对照组组间TRAb、TSAb及TSBAb阳性率比较
Table 1. The comparison of TRAb, TSAb and TSBAb positive rates bewteen study group and control group
-
观察组中无TSBAb阳性病例,对照组中有3例TSBAb阳性病例,其中伴有TRAb和TSAb异常增高的有2例,1例TSAb阳性而TRAb阴性。
-
对照组中的FT3、FT4含量明显高于观察组,TSH、TRAb的含量均明显低于观察组,两组间差异有统计学意义;而两组间TSAb和TSBAb差异无统计学意义(表 2)。
指标 对照组(n=47) 观察组(n=42) Z P FT3(pmol/L) 22.18±10.71 6.85±6.63 -6.674 P < 0.001 FT4(pmol/L) 63.28±32.93 19.77±24.75 -6.501 P < 0.001 TSH(μIU/L) 0.01±0.04 19.56±38.96 -3.332 P < 0.01 TRAb(U/L) 26.22±43.30 85.20±71.41 -3.953 P < 0.01 TSAb(U/L) 5.27±6.04 4.10±3.74 -0.337 P>0.05 TSBAb(AU/ml) 5.94±5.17 5.39±3.28 -0.234 P>0.05 注:表中,TRAb:促甲状腺素受体抗体;TSAb:甲状腺刺激抗体;TSBAb:甲状腺刺激阻断性抗体;(TSAb+TRAb)阳性表示该病例中的TRAb和TSAb同时异常增高。 表 2 观察组和对照组间血清激素及抗体水平的比较分析(x±s)
Table 2. The comparison of the serum hormones and antibody levels between study group and control group(x±s)
Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析
Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism
-
摘要:
目的 探讨和分析131I治疗Graves甲亢后早期促甲状腺素受体抗体(TRAb)和甲状腺刺激抗体(TSAb)的变化及其相关性。 方法 随机选择了89例Graves甲亢患者, 其中, 未行131I治疗的47例患者为对照组, 131I治疗后3个月的42例甲亢患者为观察组。两组患者均进行了血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)、TSH、TRAb、TSAb和甲状腺刺激阻断性抗体(TSBAb)的测定。FT3、FT4、TSH采用化学发光法测定。TRAb采用放射受体分析法测定。TSAb、TSBAb采用酶联免疫法测定。 结果 观察组和对照组中的TRAb阳性率分别为78.6%(33/42)和36.2%(17/47);TSAb、TSBAb阳性率分别为38.1%(16/42)、0(0/42)和53.2%(25/47)、6.4%(3/47);TSAb与TRAb均为阳性的病例数分别为13例、15例; TSBAb为阳性的病例数分别为0例和3例, 其中3例TSBAb阳性的患者, 2例伴有TSAb和TRAb阳性, 1例伴有TSAb阳性和TRAb阴性。 结论 131I治疗后3个月时, 多数Graves甲亢患者的血清TRAb异常增高; 131I治疗后早期异常升高的TRAb只有部分(39.4%, 13/33)显示TSAb增高, 表明131I治疗后异常升高的TRAb多数并无TSAb功能。 -
关键词:
- 格雷夫斯病 /
- 甲状腺功能亢进症 /
- 碘放射性同位素 /
- 免疫球蛋白类, 甲状腺刺激 /
- 受体, 促甲状腺素释放激素
Abstract:Objective To investigate and analyze the changes of early thyroid stimulating hormone receptor antibody(TRAb) and thyroid stimulating antibody(TSAb) after 131I treatment for Graves hyperthyroidism and their correlation. Methods Eighty-nine patients with Graves hyperthyroidism were randomly selected in this study.The patients were divided into two groups:Group 1(control group):47 patients who did not receive 131I treatment; Group 2(study group):the remaining 42 patients who received 131I treatment before 3 months.Serum FT3, FT4, TSH, TRAb, TSAb, and TSBAb values were measured for all patients in two groups.FT3, FT4, and TSH valued were determined by chemiluminescence method.TRAb values were determined by radiation receptor analysis.TSAb and TSBAb values were determined by enzyme-linked immunosorbent assay. Results The positive rates of TRAb values in study group and control group were 78.6% and 36.2% respectively.The positive rates of TSAb and TSBAb values in study group and control group were 38.1%(16/42), 0(0/42) and 53.2%(25/47), 6.4%(3/47), respectively; the number of patients with positive TSAb and TRAb simultaneously in the study and control groups were 13(16 cases with positive TSAb and 33 cases with positive TRAb) and 15 cases(25 cases with positive TSAb and 17 cases with positive TRAb), respectively; the number of patients with positive TSBAb in the study and control groups were 0 and 3 cases, respectively.Two of three patients with positive TSBAb were positive TSAb and TRAb, simultaneously, 1 of 3 patients with positive TSBAb were positive TSAb and negative TRAb. Conclusions The serum TRAb value in the majority of patients with Graves hyperthyroidism increased in 3 months after 131I treatment.The TSAb value in the part of patients with increased TRAb(39.4%, 13/33) were abnormally high, showing that increased serum TRAb in 3 months after 131I treatment could not perform the same function as TSAb. -
表 1 观察组和对照组组间TRAb、TSAb及TSBAb阳性率比较
Table 1. The comparison of TRAb, TSAb and TSBAb positive rates bewteen study group and control group
组别 例数 TRAb(U/L) TSAb(U/L) TSBAb(AU/ml) TSAb+TRAb 阳性 阴性 阳性 阴性 阳性 阴性 阳性 阳性率 对照组 47 17 30 25 22 3 44 15 88.2% 观察组 42 33 9 16 26 0 42 13 39.4% 合计 89 50 39 41 48 3 86 28 注:表中,TRAb:促甲状腺素受体抗体;TSAb:甲状腺刺激抗体;TSBAb:甲状腺刺激阻断性抗体;(TSAb+TRAb)阳性表示该病例中的TRAb和TSAb同时异常增高。 表 2 观察组和对照组间血清激素及抗体水平的比较分析(x±s)
Table 2. The comparison of the serum hormones and antibody levels between study group and control group(x±s)
指标 对照组(n=47) 观察组(n=42) Z P FT3(pmol/L) 22.18±10.71 6.85±6.63 -6.674 P < 0.001 FT4(pmol/L) 63.28±32.93 19.77±24.75 -6.501 P < 0.001 TSH(μIU/L) 0.01±0.04 19.56±38.96 -3.332 P < 0.01 TRAb(U/L) 26.22±43.30 85.20±71.41 -3.953 P < 0.01 TSAb(U/L) 5.27±6.04 4.10±3.74 -0.337 P>0.05 TSBAb(AU/ml) 5.94±5.17 5.39±3.28 -0.234 P>0.05 注:表中,TRAb:促甲状腺素受体抗体;TSAb:甲状腺刺激抗体;TSBAb:甲状腺刺激阻断性抗体;(TSAb+TRAb)阳性表示该病例中的TRAb和TSAb同时异常增高。 -
[1] Takamura Y, Nakano K, Uruno T, et al.Changes in serum TSH receptor antibody(TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy[J].Endocr J, 2003, 50(5):595-601.DOI:http://doi.org/10.1507/endocrj.50.595. [2] Jang SY, Shin DY, Lee EJ, et al.Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy[J].Yonsei Med J, 2013, 54(4):1033-1039.DOI:10.3349/ymj.2013.54.4.1033. [3] Matthews DC, Syed AA.The role of TSH receptor antibodies in the management of Graves' disease[J].Eur J Intern Med, 2011, 22(3):213-216.DOI:10.1016/j.ejim.2011.02.006. [4] 冯凭.Graves病的诊断与治疗[J].国外医学:内分泌学分册, 2004, 24(1):68-69, 72.DOI:10.3760/cma.j.issn.1673-4157.2004.01.026.
Feng P.Diagnosis and treatment of Graces[J].Section Endocrinol Foreign Med Sci, 2004, 24(1):68-69, 72. doi: 10.3760/cma.j.issn.1673-4157.2004.01.026[5] 钟兴祥, 郑吉祥, 蓝冠章, 等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志, 2011, 35(2):110-113.DOI:10.3760/cma.j.issn.1673-4114.2011.02.011.
Zhong XX, Zheng JX, Lan GZ, et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].Int J Radiat Med Nucl Med, 2011, 35(2):110-113. doi: 10.3760/cma.j.issn.1673-4114.2011.02.011[6] Lantz M, Planck T, Asman P, et al.Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onse[J].Exp Clin Endocrinol Diabetes, 2014, 122(2):113-117.DOI:10.1055/s-0033-1363193. [7] Smith BR, Sanders J, Furmaniak J.TSH receptor antibodies[J].Thyroid, 2007, 17(10):923-938.DOI:10.1089/thy.2007.0239. [8] Massart C, Sapin R, Gibassier J, et al.Intermethod variability in TSH-Receptor antibody measurement:implication for the diagnosis of graves disease and for the Follow-Up of graves ophthalmopathy[J].Clin Chem, 2009, 55(1):183-186.DOI:10.1373/clinchem.2008.115162. [9] Costagliola S, Morgenthaler NG, Hoermann R, et al.Second Generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease[J].J Clin Endocrinol Metab, 1999, 84(1):90-97.DOI:http://dx.doi.org/10.1210/jcem.84.1.5415#sthash.3Zfyif5k.dpuf. [10] Maugendre D, Massart C.Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease.Comparison with thyroid stimulating antibody bioassay[J].Clin Endocrinol(Oxf), 2001, 54(1):89-96.DOI:10.1046/j.1365-2265.2001.01197.x. [11] Takasu N, Yamada T, Takasu M, et al.Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis[J].N Engl J Med, 1992, 326(8):513-518.DOI:10.1056/NEJM199202203260803. [12] Takasu N, Oshiro C, Akamine H, et al.Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects[J].J Endocrinol Invest, 1997, 20(8):452-461. doi: 10.1007/BF03348001 [13] Kung AW, Lau KS, Kohn LD.Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive Iodine therapy[J].Thyroid, 2000, 10(10):909-917.DOI:10.1089/thy.2000.10.909. [14] Kamath C, Adlan MA, Premawardhana LD.The role of thyrotrophin receptor antibody assays in graves' disease[J/OL].J Thyroid Res, 2012: 525936[2015-07-12].http://www.hindawi.com/journals/jtr/2012/525936/.DOI:10.1155/2012/525936. [15] 张会娟, 李道明, 高冬玲, 等.Graves病异常表达HLA-DR抗原的甲状腺上皮细胞与血清TSAb的关系[J].中华内分泌代谢杂志, 2005, 21(6):546-547.DOI:10.3760/j.issn:1000-6699.2005.06.023.
Zhang HJ, Li DM, Gao DL, et al.Relationship between abnormal expression of HLA-DR antigen in thyroid epithelial cell and serum thyroid-stimulating antibodies in Graves'disease[J].Chin J Endocrinol and Metab, 2005, 21(6):546-547. doi: 10.3760/j.issn:1000-6699.2005.06.023[16] Weetman AP.Thyrotoxicosis[J].Medicine, 2013, 41(9):540-545.DOI:10.1016/j.mpmed.2013.06.012. [17] Yoshida K, Aizawa Y, Kaise N, et al.Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease[J].Clin Endocrinol(Oxf), 1998, 48(1):17-22.DOI:10.1046/j.1365-2265.1998.00330.x.